Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 9, 2007, Pages 876-880

  Tomiyama, Naoki ^a   Yasuda, Noriko ^a   Iwano, Chihiro ^a   Matzno, Sumio ^a   Matsuyama, Kenji ^a  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Apoptosis; Clofibrates; Flow cytometry; Lymphoblasts; Statins

Indexed keywords

ANNEXIN; ATORVASTATIN; AVIDIN; BEZAFIBRATE; BIOTIN; CASPASE 3; CERIVASTATIN; CLINOFIBRATE; CLOFIBRATE; DNA FRAGMENT; FLUORESCEIN ISOTHIOCYANATE; PRAVASTATIN; PROPIDIUM IODIDE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOBLAST;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE; CLOFIBRATE; DNA FRAGMENTATION; DRUG SYNERGISM; ENZYME ACTIVATION; FLOW CYTOMETRY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LYMPHOCYTES; PRAVASTATIN; PYRIDINES; PYRROLES;

EID: 34447548834     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04677.x     Document Type: Article

References (24)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990 343 : 425 30.
2. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 : 1383 9.
3. Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: The clinical implications of recent trials. Am. J. Med. 1998 104 : S2 5.
4. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 1987 317 : 1237 45.
5. Staels B, Schoonjans K, Fruchart JC, Auwerx J. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Biochimie 1997 79 : 95 9.
6. Kinoshita M. Fibric acid derivatives. Nippon Rinsho 1999 57 : 2826 3280.
7. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann. Pharmacother. 2001 35 : 908 17.
8. Liamis G, Kakafika A, Bairaktari E et al. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia. Curr. Med. Res. Opin. 2002 18 : 125 8.
9. Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am. J. Cardiol. 1999 83 : 1146.
10. Alexandridis G, Pappas GA, Elisaf MS. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am. J. Med. 2000 109 : 261 2.
11. Bermingham RP, Whitsitt TB, Smart ML, Nowak DP, Scalley RD. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. Am. J. Health. Syst. Pharm. 2000 57 : 461 4.
12. Ozdemir O, Boran M, Gokce V, Uzun Y, Kocak B, Korkmaz S. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy: A case report. Angiology 2000 51 : 695 7.
13. Lau TK, Leachman DR, Lufschanowski R. Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: Report of a case. Tex. Heart Inst. J. 2001 28 : 142 5.
14. Bruno-Joyce J, Dugas JM, MacCausland OE. Cerivastatin and gemfibrozil-associated rhabdomyolysis. Ann. Pharmacother. 2001 35 : 1016 19.
15. Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions. Use of cerivastatin and risk of rhabdomyolysis. JAMA 2004 292 : 2622 31.
16. Matsuyama K, Nakagawa K, Nakai A et al. Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method. Biol. Pharm. Bull. 2002 25 : 346 50.
17. Matzno S, Tazuya-Murayama K, Tanaka H et al. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J. Pharm. Pharmacol. 2003 55 : 795 802.
18. Yasuda N, Matzno S, Iwano C, Nishikata M, Matsuyama K. Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry. J. Pharm. Biomed. Anal. 2005 39 : 712 17.
19. Matzno S, Yasuda S, Kitada Y et al. Clofibrate-induced apoptosis is mediated by Ca2+-dependent caspase-12 activation. Life Sci. 2006 78 : 1892 9.
20. Rodwell VW, Nordstrom JL, Mitschelen JJ. Regulation of HMG-CoA reductase. Adv. Lipid. Res. 1976 14 : 1 74.
21. Sinensky M. Recent advances in the study of prenylated proteins. Biochim. Biophys. Acta 2000 1484 : 93 106.
22. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol. Rev. 2001 81 : 153 208.
23. Matzno S, Yasuda S, Juman S et al. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J. Pharm. Pharmacol. 2005 57 : 1475 84.
24. Graham DJ, Staffa JA, Shatin D et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004 292 : 2585 90.